Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: July 31, 2005 (Third Quarter of Fiscal Year 2005)
Business Overview: Cooper operates two primary segments: CooperVision (CVI), a global manufacturer of contact lenses, and CooperSurgical (CSI), a manufacturer of medical devices for women's healthcare. The reporting period is significantly impacted by the acquisition of Ocular Sciences, Inc. (Ocular) on January 6, 2005, for approximately $1.2 billion.
Key Financial Metrics
| Metric | Three Months Ended July 31, 2005 | Nine Months Ended July 31, 2005 |
|---|---|---|
| Net Sales | $222.1 million | $585.8 million |
| Gross Profit | $136.6 million (62% margin) | $359.7 million (61% margin) |
| Operating Income | $45.7 million (21% margin) | $116.3 million (20% margin) |
| Net Income | $37.4 million | $85.4 million |
| Diluted EPS | $0.79 | $1.92 |
| Cash and Equivalents | $18.0 million | $18.0 million (Balance Sheet) |
| Operating Cash Flow (9mo) | $119.2 million | |
| Total Debt | $723.7 million (Current: $42.9m; Long-term: $680.8m) | |
| Working Capital | $220.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 72% in the quarter and 63% year-to-date compared to the prior year periods. This growth is primarily attributable to the inclusion of Ocular Sciences' results since the January 6, 2005 acquisition date.
- Segment Performance: CooperVision (CVI) sales grew 90% in the quarter and 78% year-to-date. CooperSurgical (CSI) sales grew modestly by 3% in the quarter and 8% year-to-date.
- Profitability: Operating income rose 44% in the quarter and 38% year-to-date. However, gross margins decreased slightly (from 64% to 62% in the quarter) due to inventory step-up adjustments related to the Ocular acquisition ($7.2 million impact in the quarter) and restructuring costs.
- Debt Structure: Total debt increased significantly from $165.7 million to $723.7 million to fund the Ocular acquisition. The company replaced a $225 million credit facility with a new $750 million agreement.
- Restructuring: The company incurred $2.6 million in restructuring costs for the quarter and $5.2 million year-to-date, primarily related to integrating Ocular operations. Total estimated restructuring costs are projected at $25-$30 million.
Guidance, Outlook, and Risks
- Outlook: Management expects cash from operations and existing cash balances to fund future operations, capital expenditures, and debt repayments. Capital expenditures for fiscal 2005 are projected at $105-$115 million, with 70% allocated to manufacturing capacity expansion.
- Effective Tax Rate: The company expects an effective tax rate of approximately 14% for fiscal 2005, down from 21% in the prior year, driven by a shift of business to lower-tax jurisdictions and the resolution of certain tax contingencies.
- Legal Proceedings: The IRS has issued Notices of Deficiency to Ocular regarding tax years 1999-2001, asserting $44.8 million in additional taxes plus penalties. Cooper intends to vigorously contest these claims and does not believe the outcome will have a material adverse effect.
- Internal Controls: The company previously identified material weaknesses regarding derivative accounting and interactions with auditors. Management states these weaknesses have been remediated as of July 31, 2005, through personnel changes, training, and retesting of controls.
- Market Risks: Significant exposure to foreign currency fluctuations and interest rate changes. Approximately 85% of debt is now fixed-rate due to interest rate swaps entered into to hedge the new credit facility.
Investor Verification Checklist
- Acquisition Integration: Verify the progress of the Ocular Sciences integration and the realization of anticipated synergies, given the $25-$30 million restructuring cost estimate.
- Debt Covenants: Monitor compliance with the new $750 million credit agreement covenants, specifically the Total Debt to EBITDA ratio (currently 2.996:1) and the Senior Leverage Ratio (currently 2.52:1).
- Tax Litigation: Track the status of the IRS audit regarding Ocular's transfer pricing and the potential impact of the $44.8 million deficiency claim.
- Inventory Valuation: Review the impact of the inventory step-up adjustment ($16.8 million year-to-date) on future cost of sales and gross margins.
- Goodwill Impairment: Assess the $964.7 million goodwill assigned to the CooperVision segment and the company's annual impairment testing results.